Access to drug therapy and substitution between alternative antidepressants following an expansion of the California medicaid formulary

Health Policy

Volumn 65, Issue 3, 2003, Pages 301-311

  McCombs, Jeffrey S ^a   Shi, Lizheng ^b   Croghan, Thomas W ^b,c   Stimmel, Glen L ^a,d  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

Access; Drug formularies; Prior authorization

Indexed keywords

SEROTONIN UPTAKE INHIBITOR; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DRUG FORMULATION; DRUG UTILIZATION; EXPERIENCE; FEMALE; HEALTH CARE ACCESS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; OUTCOMES RESEARCH; RACE DIFFERENCE; RISK; TREATMENT OUTCOME; UNITED STATES;

EID: 0042662964     PISSN: 01688510     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8510(03)00019-8     Document Type: Article

References (21)

1. McCombs J.S., Nichol M.B., Stimmel G.L. The role of SSRI anti-depressants for treating depressed patients in the California medicaid (Medi-Cal) program. Value Health. 2:(4):1999;269-280.
2. Agency for Health Care Policy and Research. Depression in primary care: detection, diagnosis and treatment. Quick reference guide for clinicians (No. 5). Public Health Service, US Department of Health and Human Services. AHCPR Publication N0.93-0552, April 1993.
3. Croghan T.W., Johnstone B.M., Kessler R.C., Buesching D.P. Information needs for medication coverage decisions of a state medicaid program. Medical Care. 37:(4):1999;S24-31.
4. Platt-Jackson M., Croghan T.W., Melfi C.A., Lewis-Hall F. Cultural competency and psychopharmacology. Jackson V.H., Lopez L. Cultural competency in managed behavioral healthcare. 1999;187-210 Manisses Communications, Providence, RI.
5. Dechant K.L., Clissold S.P. Paroxetine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depressive illness. Drugs. 41:1991;225-253.
6. Murdoch D., McTavish D. Sertraline: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in depression and obsessive-compulsive disorder. Drugs. 44:1992;604-624.
7. Boyer W.F., Blumhardt C.L. The safety profile of paroxetine. Journal of Clinical Psychiatry. 53:(Suppl):1992;61-66.
8. Stokes P.E. Fluoxetine: a five year review. Clinical Therapy. 15:1993;216-243.
9. Leonard B.E. The comparative pharmacology of new antidepressants. Journal of Clinical Psychiatry. 54:1993;3-15.
10. Nemeroff C.B. Evolutionary trends in the pharmacotherapeutic management of depression. Journal of Clinical Psychiatry. 55:(Suppl):1994;3-15.
11. Casey D.E. Striking a balance between safety and efficacy: experience with the SSRI sertraline. International Clinical Psychopharmacology. 9:(Suppl):1994;5-31.
12. Andrews J.M., Nemeroff C.B. Contemporary management of depression. American Journal of Medicine. 97:(6A):1994;24S-32S.
13. Rudorfer M.V., Manji H.K., Potter W.Z. Comparative tolerability profiles of the newer versus older antidepressants. Drug Safety. 10:1994;18-46.
14. DuBois R.W., et al. Explaining drug spending trends: does perception meet reality? Health Affairs (March/April). 20:(2):2001;231-239.
15. Berndt E.R. The US pharmaceutical industry: why significant growth in times of cost containment. Health Affairs (March/April). 20:(2):2001;100-114.
16. Katon W., von Korff M., Lin E., et al. Distressed high utilizers of medical care: DSM-III-R diagnoses and treatment needs. General Hospital Psychiatry. 12:1990;355-362.
17. Allison P.D. Overdispersion. Logistic regression using the SAS system. 1999;103-110 SAS Institute Inc, Cary, NC. Chapter 4.6.
18. Croghan T.W. The controversy of rising expenditures for antidepressants. Health Affairs (March/April). 20:(2):2001;129-135.
19. Heckman J.J. Treatment selection as a specification error. Econometrica. 47:(1):1979;153-161.
20. Viverberg W.P.M. Educational investments and returns for women and men in Cote d'Ivorie. Journal of Human Resource. 28:(4):1993;933-974.
21. Viverberg W.P.M. Double selection criteria with multiple alternatives: migration, work-status, and wage. International Economic Review. 36:(1):1995;159-185.